Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS Inc. (SCYX) is a clinical-stage biotechnology company advancing innovative therapies for severe fungal infections. This page aggregates official news and press releases related to their antifungal pipeline, including ibrexafungerp and SCY-247 development milestones.
Investors and healthcare professionals will find timely updates on clinical trial data, regulatory submissions, and strategic partnerships. Content includes earnings reports, research publications, and manufacturing announcements, all sourced directly from the company.
Key areas covered: Phase III trial results, FDA communications, intellectual property updates, and collaborative research initiatives. Bookmark this page for streamlined access to SCYNEXIS's latest developments in antifungal therapeutics.
SCYNEXIS (NASDAQ: SCYX) announced it will receive a $10 million milestone payment from GSK, triggered by the delivery of final clinical study reports for the completed FURI, CARES, and NATURE trials. This payment is part of their exclusive license agreement for ibrexafungerp. Results from the FURI and CARES studies are positive and consistent with previous interim analyses. SCYNEXIS reiterates its cash runway of over two years and plans to advance SCY-247, its next-generation fungerp, into clinical trials later this year. The company has previously received $115 million from GSK and is eligible for up to $323 million more in potential payments, plus tiered royalties on ibrexafungerp sales.
SCYNEXIS, a biotechnology company, reported its first-quarter financial results for 2024, ending with $94.2 million in cash, with a projected cash runway of over two years. They continue to progress with SCY-247's development and anticipate a Phase I trial by 2024. The company is working on new manufacturing agreements due to clinical hold issues with ibrexafungerp and presented promising preclinical data for SCY-247 at a conference. SCYNEXIS expects to deliver study reports to GSK, triggering a $10 million milestone payment. Financially, revenue consisted of $1.4 million from a license agreement with GSK. Research and development expenses increased slightly, while SG&A expenses decreased. Net income for Q1 2024 was $0.4 million compared to a loss in the same period in 2023.
SCYNEXIS, Inc. presented preclinical data on its second-generation fungerp SCY-247 at the ESCMID Global 2024 congress. SCY-247 showed efficacy in treating invasive candidiasis and displayed in vitro activity against a wide range of pathogenic fungi. The company aims to address the need for new antifungal treatments, especially for drug-resistant infections. The positive data further solidify SCY-247's potential in combating difficult-to-treat infections.
FAQ
What is the current stock price of Scynexis (SCYX)?
What is the market cap of Scynexis (SCYX)?
